Trastuzumab Deruxtecan in <i>HER2</i> -Mutant Non–Small-Cell Lung Cancer
Bob T. Li(Memorial Sloan Kettering Cancer Center), Egbert F. Smit(Cornell University), Yasushi Goto(Cornell University), Kazuhiko Nakagawa(Cornell University), Hibiki Udagawa(Cornell University), Julien Mazières(Cornell University), Misako Nagasaka(Cornell University), Lyudmila Bazhenova(Cornell University), Andreas Saltos(Cornell University), Enriqueta Felip(Hebron University), Jose M. Pacheco(Cornell University), M. Pérol(Cornell University), Luis Paz‐Ares(Universidad Complutense de Madrid), Kapil Saxena(Cornell University), Ryota Shiga(Cornell University), Yingkai Cheng(Cornell University), Suddhasatta Acharyya(Cornell University), Patrik Vitazka(Cornell University), Javad Shahidi(Cornell University), David Planchard(Cornell University), Pasi A. Jänne(Cornell University)
Cited by 955Open Access
Abstract
BACKGROUND: -mutant NSCLC have not been investigated extensively. METHODS: -mutant NSCLC that was refractory to standard treatment. The primary outcome was objective response as assessed by independent central review. Secondary outcomes included the duration of response, progression-free survival, overall survival, and safety. Biomarkers of HER2 alterations were assessed. RESULTS: amplification. CONCLUSIONS: -mutant NSCLC. The safety profile included interstitial lung disease that was fatal in two cases. Observed toxic effects were generally consistent with those in previously reported studies. (Funded by Daiichi Sankyo and AstraZeneca; DESTINY-Lung01 ClinicalTrials.gov number, NCT03505710.).